Mechanisms of resistance to PARP inhibitors - an evolving challenge in oncology

Abstract

Poly-adenosine diphosphate ribose polymerase inhibitors (PARPi) lead to synthetic lethality when used in cancers harbouring a BRCA mutation or homologous recombination deficiency. There are now four PARPi approved by the Food and Drug Administration for therapeutic use is ovarian and breast cancer. In addition to this, there is data supporting its use in pancreatic adenocarcinoma and prostate cancer. However, development of resistance to PARPi limits the duration of response. Key mechanisms found to date include: (1) restoration of homologous recombination; (2) changes in PARP1; (3) suppression of non-homologous end joining; (4) replication fork protection; and (5) drug concentration. Gaining a better understanding of resistance mechanisms may guide combination therapies to overcome the resistance and improve the efficacy of PARPi. The purpose of this review is to describe the resistance mechanisms to PARPi and discuss their early detection.

Keywords

Poly-adenosine diphosphate ribose polymerase inhibition / resistance mechanisms / homologous recombination / BRCA reversion / ovarian cancer

References

[1] Ledermann J,Gourley C,Vergote I.Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer..N Engl J Med2012;366:1382-92

[2] Ledermann J,Gourley C,Vergote I.Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial..Lancet Oncol2014;15:852-61

[3] Mirza MR,Herrstedt J,Mahner S.Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer..N Engl J Med2016;375:2154-64

[4] Ledermann J,Lorusso D,Oaknin A.LBA40_PRARIEL3: a phase 3, randomised, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma (OC)..Ann Oncol2017;28:

[5] Pujade-Lauraine E,Selle F,Penson RT.Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial..Lancet Oncol2017;18:1274-84

[6] Kaufman B,Schmutzler RK,Friedlander M.Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation..J Clin Oncol2015;33:244-50 PMCID:PMC6057749

[7] Robson M,Senkus E,Domchek SM.Olaparib for metastatic breast cancer in patients with a germline BRCA mutation..N Engl J Med2017;377:523-33

[8] Moore K,Scambia G,Oaknin A.Maintenance Olaparib in patients with newly diagnosed advanced ovarian cancer..N Engl J Med2018;379:2495-505

[9] Domchek SM,Shapira-Frommer R,Audeh MW.Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy..Gynecol Oncol2016;140:199-203 PMCID:PMC4992984

[10] Oza AM,Oaknin A,McNeish IA.Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2..Gynecol Oncol2017;147:267-75

[11] Coleman RL,Lorusso D,Oaknin A.Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial..Lancet2017;390:1949-61 PMCID:PMC5901715

[12] Litton JK,Ettl J,Gonçalves A.Talazoparib in patients with advanced breast cancer and a germline BRCA mutation..N Engl J Med2018;379:753-63

[13] Food and Drug AdministrationVeliparib receives orphan drug designation for treatment of advanced squamous non-small cell lung cancer..FDA Orphan Drug Designations and Approvals2016;

[14] Murai J,Das BB,Zhang Y.Trapping of PARP1 and PARP2 by clinical PARP inhibitors..Cancer Res2012;72:5588-99

[15] Friedlander M,Markman B,Harnett P.Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial..Lancet Oncol2019;

[16] Ciardiello F,Bendell JC,Brachmann RK.A phase III, double-blind, randomized study of pamiparib versus placebo as maintenance therapy in patients with inoperable, locally advanced, or metastatic gastric cancer (GC) that responded to platinum-based first-line chemotherapy..J Clin Oncol2019;37:TPS173

[17] Chowdhury S,Gross M,Cruz-Correa M.Pamiparib, an investigational PARP inhibitor, in patients with metastatic castration-resistant prostate cancer (mCRPC) and a circulating tumor cell (CTC) homologous recombination deficiency (HRD) phenotype or BRCA defects: a trial in progress..J Clin Oncol2019;37:TPS5086

[18] Shen Y,Feng Y,Bajrami I.BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency..Clin Cancer Res2013;19:5003-15 PMCID:PMC6485449

[19] Berek JS,Peen U,Mahner S.Safety and dose modification for patients receiving niraparib..Ann Oncol2018;29:1784-92

[20] Golan T,Reni M,Macarulla T.Maintenance Olaparib for germline BRCA-mutated metastatic pancreatic cancer..N Engl J Med2019;381:317-27

[21] Mateo J,Sandhu S,Mossop H.DNA-repair defects and Olaparib in metastatic prostate cancer..N Engl J Med2015;373:1697-708 PMCID:PMC5228595

[22] Barkauskaite E,Ahel I.Structures and mechanisms of enzymes employed in the synthesis and degradation of PARP-dependent protein ADP-ribosylation..Mol Cell2015;58:935-46

[23] Weaver AN.Beyond DNA repair: additional functions of PARP-1 in Cancer..Front Oncol2013;3:290 PMCID:PMC3841914

[24] McCann KE.Poly-ADP-ribosyl-polymerase inhibitor resistance mechanisms and their therapeutic implications..Curr Opin Obstet Gynecol2019;31:12-7

[25] Haynes B,Lee JM.Restored replication fork stabilization, a mechanism of PARP inhibitor resistance, can be overcome by cell cycle checkpoint inhibition..Cancer Treat Rev2018;71:1-7

[26] Gogola E,de Ruiter JR,Schmid JA.Selective loss of PARG restores parylation and counteracts PARP inhibitor-mediated synthetic lethality..Cancer Cell2018;33:1078-93.e12

[27] D’Andrea AD.Mechanisms of PARP inhibitor sensitivity and resistance..DNA Repair (Amst)2018;71:172-6

[28] Jiang X,Li W,Zhang Z.PARP inhibitors in ovarian cancer: sensitivity prediction and resistance mechanisms..J Cell Mol Med2019;23:2303-13 PMCID:PMC6433712

[29] Patel AG,Kaufmann SH.Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells..Proc Natl Acad Sci U S A2011;108:3406-11 PMCID:PMC3044391

[30] Thomas A,Pommier Y.The evolving landscape of predictive biomarkers of response to PARP inhibitors..J Clin Invest2018;128:1727-30 PMCID:PMC5919798

[31] Hopkins TA,Ellis PA,DiGiammarino EL.PARP1 trapping by PARP inhibitors drives cytotoxicity in both cancer cells and healthy bone marrow..Mol Cancer Res2019;17:409-19

[32] Gelmon KA,Mackay H,Robidoux A.Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study..Lancet Oncol2011;12:852-61

[33] Fong PC,Boss DS,Mergui-Roelvink M.Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval..J Clin Oncol2010;28:2512-9

[34] Sandhu SK,Wilding G,Baird RD.The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial..Lancet Oncol2013;14:882-92

[35] Norquist B,Pennil CC,Gross J.Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas..J Clin Oncol2011;29:3008-15 PMCID:PMC3157963

[36] Lheureux S,Burnier JV,Shaw PA.Somatic BRCA1/2 recovery as a resistance mechanism after exceptional response to poly (ADP-ribose) polymerase inhibition..J Clin Oncol2017;35:1240-9

[37] Ter Brugge P,van der Burg E,de Maaker M.Mechanisms of therapy resistance in patient-derived xenograft models of BRCA1-deficient breast cancer..J Natl Cancer Inst2016;108:

[38] Bouwman P.Molecular pathways: how can BRCA-mutated tumors become resistant to PARP inhibitors?.Clin Cancer Res2014;20:540-7

[39] Gupta R,Narita T,Stanlie A.DNA repair network analysis reveals shieldin as a key regulator of NHEJ and PARP inhibitor sensitivity..Cell2018;173:972-88.e23

[40] Noordermeer SM,Setiaputra D,Pettitt SJ.The shieldin complex mediates 53BP1-dependent DNA repair..Nature2018;560:117-21 PMCID:PMC6141009

[41] Setiaputra D.Shieldin - the protector of DNA ends..EMBO Rep2019;20: PMCID:PMC6501030

[42] Meghani K,Detappe A,Gogola E.Multifaceted impact of microRNA 493-5p on genome-stabilizing pathways induces platinum and PARP inhibitor resistance in BRCA2-mutated carcinomas..Cell Rep2018;23:100-11 PMCID:PMC5908239

[43] Cruz C,Gutierrez-Enriquez S,Ibrahim YH.RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer..Ann Oncol2018;29:1203-10 PMCID:PMC5961353

[44] Kondrashova O,Shield-Artin K,Teng NNH.Secondary somatic mutations restoring RAD51C and RAD51D associated with acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma..Cancer Discov2017;7:984-98 PMCID:PMC5612362

[45] Peng G,Mo W,Park YY.Genome-wide transcriptome profiling of homologous recombination DNA repair..Nat Commun2014;5:3361 PMCID:PMC4017859

[46] Esposito MT,Fung TK,Wilson A.Synthetic lethal targeting of oncogenic transcription factors in acute leukemia by PARP inhibitors..Nat Med2015;21:1481-90

[47] Murai J,Yu GK,Tang SW.Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition..Oncotarget2016;7:76534-50 PMCID:PMC5340226

[48] Lok BH,Schneeberger VE,Desmeules P.PARP inhibitor activity correlates with SLFN11 expression and demonstrates synergy with temozolomide in small cell lung cancer..Clin Cancer Res2017;23:523-35 PMCID:PMC5241177

[49] Makvandi M,Schwartz L,Xu K.A PET imaging agent for evaluating PARP-1 expression in ovarian cancer..J Clin Invest2018;128:2116-26 PMCID:PMC5919879

[50] Pettitt SJ,Brandsma I,Song F.Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance..Nature communications2018;9:1849 PMCID:PMC5945626

[51] Du Y,Wei Y,Wang HL.Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors..Nat Med2016;22:194-201 PMCID:PMC4754671

[52] Gilabert M,Ginestier C,Audebert S.Poly(ADP-ribose) polymerase 1 (PARP1) overexpression in human breast cancer stem cells and resistance to olaparib..PLoS One2014;9:e104302 PMCID:PMC4140711

[53] Hjortkjær M,Jakobsen A,Søgaard-Andersen E.The prognostic value of BRCA1 and PARP expression in epithelial ovarian carcinoma: immunohistochemical detection..Int J Gynecol Pathol2017;36:180-9

[54] Choi YE,Brault ME,He YJ.Platinum and PARP inhibitor resistance due to overexpression of microRNA-622 in BRCA1-mutant ovarian cancer..Cell Rep2016;14:429-39 PMCID:PMC4731274

[55] Ray Chaudhuri A,Ding X,Duarte AA.Replication fork stability confers chemoresistance in BRCA-deficient cells..Nature2016;535:382-7 PMCID:PMC4959813

[56] Rondinelli B,Yucel H,van de Ven M.EZH2 promotes degradation of stalled replication forks by recruiting MUS81 through histone H3 trimethylation..Nat Cell Biol2017;19:1371-8

[57] Durmus S,van Esch A,Beijnen JH.Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1) restrict oral availability and brain accumulation of the PARP inhibitor rucaparib (AG-014699)..Pharm Res2015;32:37-46

[58] Oplustilova L,Mistrik M,Simkova D.Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment..Cell Cycle2012;11:3837-50 PMCID:PMC3495826

[59] Rottenberg S,Kersbergen A,Nygren AO.High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs..Proc Natl Acad Sci U S A2008;105:17079-84 PMCID:PMC2579381

[60] Jaspers JE,Boon U,van Deemter L.Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors..Cancer Discov2013;3:68-81

[61] Montoni A,Pouliot E.Resistance to PARP-Inhibitors in cancer therapy..Front Pharmacol2013;4:18 PMCID:PMC3583007

[62] Morgillo F,Fasano M.Mechanisms of resistance to EGFR-targeted drugs: lung cancer..ESMO Open2016;1:e000060 PMCID:PMC5070275

[63] Christie EL,Doig K,Dawson SJ.Reversion of BRCA1/2 germline mutations detected in circulating tumor DNA from patients with high-grade serous ovarian cancer..J Clin Oncol2017;35:1274-80

[64] Swisher EM,Oza AM,Giordano H.Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial..Lancet Oncol2017;18:75-87

[65] Marijon H,Ding L,Gery S.Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: higher synergism in BRCA mutated cells..Biomed Pharmacother2018;99:543-51

[66] Bitler BG,Wheeler LJ.PARP inhibitors: clinical utility and possibilities of overcoming resistance..Gynecol Oncol2017;147:695-704 PMCID:PMC5698126

[67] Ivy SP,Lee JM,Kohn EC.Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer..Expert Opin Investig Drugs2016;25:597-611

[68] Mo W,Lin CC,Peng Y.mTOR inhibitors suppress homologous recombination repair and synergize with PARP inhibitors via regulating SUV39H1 in BRCA-proficient triple-negative breast cancer..Clin Cancer Res2016;22:1699-712 PMCID:PMC4858320